(RSV) is a common cause of lower respiratory tract infection (LRTI) and is responsible for a high burden of hospital admission and mortality in children. RSV–LRTI is also associated with long-term ...
GSK released data from a Phase 3 trial evaluating the co-administration of Arexvy and Shingrix vaccines in adults 50+. The ...
Background: Respiratory syncytial virus (RSV) vaccines could reduce disease burden and costs in older Canadian adults, but vaccination program cost-effectiveness is unknown. We evaluated the ...
A vaccine to protect babies and older adults against a common but potentially dangerous respiratory infection is set to be ...
As the cold and flu season approaches, LeadingAge has announced a partnership with the U.S. Department of Health and Human Services (HHS) to launch the "Risk Less. Do More.” campaign. This national ...
CHICAGO, CA, UNITED STATES, September 16, 2024 /EINPresswire / -- The global respiratory syncytial virus (RSV) <a target=_blank href=htt ...
released topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of Arexvy (Respiratory Syncytial Virus Vaccine) when co ...